Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours

Next Previous
Trial Profile

A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belinostat (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Bladder cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Valerio Therapeutics

Most Recent Events

  • 22 Dec 2009 Actual patient number changed from 36 to 80 as reported by ClinicalTrials.gov.
  • 23 Oct 2008 Interim results in 7 patients reported at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' conference, according to a TopoTarget media release.
  • 21 Oct 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top